In Focus: Advances in Non-Oral Modalities for the Treatment of Acute Migraine
Migraine treatment includes both preventive therapy, aimed at reducing attack frequency and severity, and acute therapy, for aborting attacks. For acute therapy, the most widely used drugs are NSAIDs and triptans. Routes of triptan administration include oral, intranasal, suppository, subcutaneous, and transdermal iontophoretic, as well as a variety of device-enhanced delivery options. Relatively slow onset of action remains a limitation for these formulations, except for the injectable delivery. Novel routes of delivery, such as intradermal, are in development, holding the promise of rapid absorption into the systemic circulation and, thus, rapid relief. Ultimately, the abundance of delivery options provides more choices to patients with migraine.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with migraine.
Upon completion of this activity, participants will be better able to do the following:
- Discuss currently available non-oral treatments for acute migraine and their safety and efficacy
- Identify non-oral treatments for acute migraine in late-stage development
|David W. Dodick, MD (Program Chair) |
Department of Neurology
Stewart J. Tepper, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Relationship Identified With:|
David W. Dodick, MD
Consultant/Advisor: Acorda Therapeutics, Alder BioPharmaceuticals Inc., Allergan Inc., Amgen Inc, Autonomic Technologies Inc., BioCentric, Inc., Biohaven Pharmaceutical, Boston Scientific Corporation, Charleston Laboratories Inc., CoLucid Pharmaceuticals, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, eNeura, Inc., GBS, Inc., Insys Therapeutics, Inc., Ladenburg Thalmann Financial Services Inc, Magellan Health, Inc., Merck & Co., Inc., Pfizer Inc, Promius Pharma, LLC, Teva Pharmaceutical Industries Ltd., Tonix Pharmaceuticals Holding Corp, Trigemina, Inc, Xenon Pharmaceuticals Inc, Zosano Pharma Corporation
Stock Ownership: EPIEN Medical, Inc, King-Devick Technologies, Inc.,Migraine Buddy, Nocira, SecondOpinions.com
Royalties/Patents: Cambridge University Press, Oxford University Press
Stewart J. Tepper, MD
Consultant/Advisor: Acorda Therapeutics, Alder BioPharmaceuticals Inc., Allergan Inc., Amgen Inc, Autonomic Technologies Inc., Avanir Pharmaceuticals, Inc., BioVision, Charleston Laboratories Inc., Dr. Reddy’s Laboratories Ltd, electroCore, LLC, Eli Lilly and Company, eNeura, Inc., Kimberly Clark Corporation, PERNIX Therapeutics, Pfizer Inc; Scion NeuroStim LLC, Teva Pharmaceutical Industries Ltd, Zosano Pharma Corporation
Grant/Research Support: Alder BioPharmaceuticals Inc., Allergan Inc., Amgen Inc, Autonomic Technologies Inc., Avanir Pharmaceuticals, Inc.; electroCore, LLC, eNeura, Inc., Teva Pharmaceutical Industries Ltd., Zosano Pharma Corporation
Employment Affiliation: American Headache Society Royalties/Patents: Autonomic Technologies Inc., Springer Publishing Company
Stock Ownership: Autonomic Technologies Inc.
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Zosano Pharma Corporation.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and Zosano Pharma Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician